RxDoctor Payments Data

Nicole Angel, MD

Hematology & Oncology · Mobile, ALNPI 1457305229

Payments from drug & device makers

$9,556in general payments, 2019–2025

Across 535 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • AstraZeneca$657
  • Amgen$595
  • Merck$583
  • Incyte Corporation$419
  • Genentech USA, Inc.$409
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$9,25397%
  • Education$3033%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$9,556 in reported general payments places this provider in the 40th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama

Medicare billing

Part B allowed, 2024
$2,525,334
Medicare patients
517
Services billed
122,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate69$959,490
BrukinsaZanubrutinib31$465,630
RevlimidLenalidomide22$443,207
TibsovoIvosidenib12$405,808
Lenalidomide21$257,078
InqoviDecitabine/Cedazuridine35$238,897
VenclextaVenetoclax26$213,499
Imatinib Mesylate21$106,056
JakafiRuxolitinib Phosphate11$92,982
Everolimus11$17,655
EliquisApixaban24$13,700
XareltoRivaroxaban18$11,012
Fentanyl70$9,117
Tamoxifen Citrate70$2,378
Anastrozole145$2,302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaCalquence$657$959,49069 claims
Beigene USA, Inc.Brukinsa$183$465,63031 claims
Bristol Myers SquibbRevlimid$323$443,20722 claims
Servier Pharmaceuticals LLCTibsovo$14$405,80812 claims
AbbVieVenclexta$144$213,49926 claims
Incyte CorporationJakafi$419$92,98211 claims
PfizerEliquis$106$13,70024 claims
Johnson & JohnsonXarelto$346$11,01218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 177 hematology & oncology providers in Alabama.

Other hematology & oncology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →